PureTech Health PLC (LON:PRTC) revealed it has been granted clearance by the US Food and Drug Administration (FDA) for EndeavorRx, its video game-based treatment for children aged 8-12 with attention-deficit/hyperactivity disorder (ADHD).
The group noted that research has shown that after four weeks of treatment, one-third of children no longer had a measurable attention deficit on at least one measure of objective attention.
Half of parents saw a clinically meaningful change in their child's day-to-day impairments after one month of usage, increasing to 68% after two months, it added.
“EndeavorRx is the first digital therapeutic intended to improve symptoms associated with ADHD, and it is also the first game-based therapeutic to be granted marketing authorisation by the FDA for any type of condition,” Daphne Zohar, founder and chief executive officer of FTSE 250-listed PureTech said in a statement.
Analysts at Peel Hunt factor in a peak treatment rate of 300,000 patients for peak annual in-market revenue of US$390mln.
Shares jumped 5% to 253p early on Tuesday.
--Adds analyst's comment, shares--